SCHEMBL25220184

SCHEMBL25220184

CC(C)(C)OC(=O)N1CCN(c2nc3cc(Br)ccc3c(=O)[nH]2)CC1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.50
MGLL Q99685 16/20 0.49
NAMPT P43490 1/20 0.49
BACE1 P56817 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26170030 0.92 NAMPT (0.51) KCNH2MGLLNAMPTBACE1
SCHEMBL29784222 0.88 MGLL (0.53) KCNH2MGLLNAMPT
SCHEMBL20898197 0.88 MGLL (0.53) KCNH2MGLLNAMPT
SCHEMBL31569825 0.86 KCNH2 (0.57) KCNH2NAMPTBACE1
SCHEMBL20897769 0.85 HTR3A (0.62) MGLL
SCHEMBL20897501 0.82 MGLL (0.54) MGLLNAMPT
SCHEMBL29784272 0.82 MGLL (0.54) MGLLNAMPT
SCHEMBL20897546 0.81 HTR3A (0.65) KCNH2MGLLNAMPT
SCHEMBL29784276 0.81 HTR3A (0.65) KCNH2MGLLNAMPT
SCHEMBL20897590 0.81 MGLL (0.54) MGLLNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167093-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-06-01 US disclosed
US-20230167093-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167093-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 KCNH2 4745/4885MGLL 3186/4885NAMPT 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.